Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study

PURPOSE: This study aimed to compare progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) in Heng intermediate-risk patients with metastatic renal cell carcinoma (mRCC) treated with first-line immunotherapy (IT) or targeted therapy (TT). MATERIALS AND METHODS: F...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sung Han, Lee, Dong-Eun, Joung, Jae Young, Seo, Ho Kyung, Lee, Kang Hyun, Chung, Jinsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052413/
https://www.ncbi.nlm.nih.gov/pubmed/32158965
http://dx.doi.org/10.4111/icu.2020.61.2.146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052413/
https://www.ncbi.nlm.nih.gov/pubmed/32158965
http://dx.doi.org/10.4111/icu.2020.61.2.146

Ejemplares similares